Oxford Global Tumour Microenvironment 2023
Uncover how companies are furthering their understanding of the tumour microenvironment through the latest technologies, including spatial imaging and novel biomarkers. Gain insights in emerging therapeutic opportunities through targeting the tumour microenvironment with immunooncology.
The Conference Forum: Immuno-Oncology 360°
Immuno-Oncology (IO) 360° takes a strategic look at the business and scientific aspects of Immuno-Oncology. With significant in-put from Lead Advisors Dr. Axel Hoos (former CEO of Scorpion Therapeutics) and Dr. James Gulley (NCI,) the conference examines the current landscape, and reports on the latest advancements in IO to improve and accelerate clinical trials. The audience is comprised of roughly 500 top executives at Pharma companies and Biotechs, as well as the financial community, consultants and leading research organizations in the field of Immuno-Oncology.